Mason Carrico
Stock Analyst at Stephens & Co.
(1.92)
# 3,049
Out of 4,876 analysts
77
Total ratings
35.29%
Success rate
-7.23%
Average return
Main Sectors:
Stocks Rated by Mason Carrico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VCEL Vericel | Reiterates: Overweight | $67 | $41.66 | +60.83% | 3 | Jun 16, 2025 | |
| ILMN Illumina | Reiterates: Overweight | $105 | $94.16 | +11.51% | 8 | May 20, 2025 | |
| PACB Pacific Biosciences of California | Reiterates: Overweight | $1.8 | $1.29 | +39.53% | 5 | May 15, 2025 | |
| TXG 10x Genomics | Reiterates: Overweight | $14 | $11.70 | +19.66% | 6 | May 15, 2025 | |
| HOLX Hologic | Maintains: Overweight | $77 → $70 | $65.11 | +7.51% | 4 | May 13, 2025 | |
| CDNA CareDx | Reiterates: Overweight | $40 | $19.29 | +107.36% | 10 | May 5, 2025 | |
| GKOS Glaukos | Maintains: Overweight | $140 → $115 | $101.06 | +13.79% | 1 | May 2, 2025 | |
| VCYT Veracyte | Reiterates: Overweight | $45 | $26.81 | +67.85% | 7 | Mar 26, 2025 | |
| GH Guardant Health | Reiterates: Overweight | $55 | $50.03 | +9.93% | 5 | Mar 26, 2025 | |
| AKYA Akoya Biosciences | Downgrades: Equal-Weight | $3.5 → $1.8 | $1.32 | +36.36% | 6 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $3.55 | +69.01% | 2 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $17 | $16.81 | +1.13% | 2 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $52 | $40.84 | +27.33% | 2 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $20 | $5.33 | +275.23% | 4 | Jan 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $41 | $19.78 | +107.28% | 7 | Jan 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $125 | $168.17 | -25.67% | 4 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $19 | $7.16 | +165.36% | 1 | Jul 30, 2024 |
Vericel
Jun 16, 2025
Reiterates: Overweight
Price Target: $67
Current: $41.66
Upside: +60.83%
Illumina
May 20, 2025
Reiterates: Overweight
Price Target: $105
Current: $94.16
Upside: +11.51%
Pacific Biosciences of California
May 15, 2025
Reiterates: Overweight
Price Target: $1.8
Current: $1.29
Upside: +39.53%
10x Genomics
May 15, 2025
Reiterates: Overweight
Price Target: $14
Current: $11.70
Upside: +19.66%
Hologic
May 13, 2025
Maintains: Overweight
Price Target: $77 → $70
Current: $65.11
Upside: +7.51%
CareDx
May 5, 2025
Reiterates: Overweight
Price Target: $40
Current: $19.29
Upside: +107.36%
Glaukos
May 2, 2025
Maintains: Overweight
Price Target: $140 → $115
Current: $101.06
Upside: +13.79%
Veracyte
Mar 26, 2025
Reiterates: Overweight
Price Target: $45
Current: $26.81
Upside: +67.85%
Guardant Health
Mar 26, 2025
Reiterates: Overweight
Price Target: $55
Current: $50.03
Upside: +9.93%
Akoya Biosciences
Mar 25, 2025
Downgrades: Equal-Weight
Price Target: $3.5 → $1.8
Current: $1.32
Upside: +36.36%
Mar 19, 2025
Reiterates: Overweight
Price Target: $6
Current: $3.55
Upside: +69.01%
Mar 18, 2025
Reiterates: Equal-Weight
Price Target: $17
Current: $16.81
Upside: +1.13%
Mar 6, 2025
Reiterates: Overweight
Price Target: $52
Current: $40.84
Upside: +27.33%
Jan 16, 2025
Reiterates: Equal-Weight
Price Target: $20
Current: $5.33
Upside: +275.23%
Jan 2, 2025
Reiterates: Overweight
Price Target: $41
Current: $19.78
Upside: +107.28%
Aug 9, 2024
Reiterates: Overweight
Price Target: $125
Current: $168.17
Upside: -25.67%
Jul 30, 2024
Reiterates: Overweight
Price Target: $19
Current: $7.16
Upside: +165.36%